RCKT vs. SWTX, RARE, AKRO, ALVO, IMVT, VKTX, RYTM, CRNX, MRUS, and SRRK
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs.
SpringWorks Therapeutics (NASDAQ:SWTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.
SpringWorks Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
In the previous week, SpringWorks Therapeutics had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 8 mentions for SpringWorks Therapeutics and 5 mentions for Rocket Pharmaceuticals. SpringWorks Therapeutics' average media sentiment score of 1.19 beat Rocket Pharmaceuticals' score of 1.10 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
Rocket Pharmaceuticals has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -134.73%. SpringWorks Therapeutics' return on equity of -46.74% beat Rocket Pharmaceuticals' return on equity.
Rocket Pharmaceuticals has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
SpringWorks Therapeutics presently has a consensus price target of $73.20, suggesting a potential upside of 54.14%. Rocket Pharmaceuticals has a consensus price target of $43.00, suggesting a potential upside of 445.69%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than SpringWorks Therapeutics.
98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 7.6% of SpringWorks Therapeutics shares are held by insiders. Comparatively, 28.5% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Rocket Pharmaceuticals received 290 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 73.33% of users gave Rocket Pharmaceuticals an outperform vote while only 71.62% of users gave SpringWorks Therapeutics an outperform vote.
Summary
Rocket Pharmaceuticals beats SpringWorks Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 3/28/2025 by MarketBeat.com Staff
